WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] => all
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 5065
[post_author] => 4
[post_date] => 2026-09-01 14:03:32
[post_date_gmt] => 2026-09-01 18:03:32
[post_content] =>
Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.
BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.
Application deadline: October 29, 2026, 5:00pm ET
For info sessions, eligibility and deadlines visit our REACH Website and FAQ.
The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.
Questions? Reach out to our program contacts or sign up for office hours:
Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here
Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here
[post_title] => BioREACH: Translational Research Funding Opportunity
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => bioreach-translational-research-funding-opportunity
[to_ping] =>
[pinged] =>
[post_modified] => 2026-09-04 11:55:36
[post_modified_gmt] => 2026-09-04 15:55:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=5065
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 3083
[post_author] => 3
[post_date] => 2018-11-16 14:26:57
[post_date_gmt] => 2018-11-16 14:26:57
[post_content] => Update courtesy of BBC Entrepreneurial Training and Consulting
NIH is strongly encouraging small businesses to contact the appropriate Institute or Center early in their application planning to ensure their technology is a priority for the Institute/Center.
An updated SBIR/STTR Application Guide with additional instructions for SBIR Direct Phase II application preparation and submission will be posted by November 26, 2018. The following sections of each FOA are changed:
Part 2, Section I. Funding Opportunity Description The following has been added at the end of the section for each FOA:
PA-18-573 The following Components will not accept an SBIR Direct-to-Phase II submission:
- National Institute of Nursing Research (NINR)
- National Center for Complementary and Integrative Health (NCCIH)
PA-18-574 The following Components will not accept an SBIR Direct-to-Phase II submission:
- National Institute of Environmental Health Sciences (NIEHS )
- National Institute of Nursing Research (NINR)
- National Center for Complementary and Integrative Health (NCCIH)
- Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP)
- Centers for Disease Control and Prevention (CDC) (All Components of CDC)
- U.S. Food and Drug Administration (FDA) (All Components of FDA)
Part 2, Section II. Award Information for both PA-18-573 and PA-18-574. Application types now allowed are:
- New (Phase I, Fast-Track)
- New (Direct Phase II)
- Renewal (Phase II)
- Resubmission (all phases)
- Phase IIB Competing Renewal (Phase IIB)
- Revision
The OER Glossary and the SF424 (R&R) SBIR/STTR Application Guide provide details on these application types.
[post_title] => Important SBIR/STTR Information Update from NIH
[post_excerpt] => An updated SBIR/STTR Application Guide with additional instructions for SBIR Direct Phase II application preparation and submission will be posted by November 26, 2018.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => important-sbirsttr-information-update-from-nih
[to_ping] =>
[pinged] =>
[post_modified] => 2018-11-16 14:26:57
[post_modified_gmt] => 2018-11-16 14:26:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=3083
[menu_order] => 110
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4804
[post_author] => 4
[post_date] => 2025-03-20 12:10:54
[post_date_gmt] => 2025-03-20 16:10:54
[post_content] =>
The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.
The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.
The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.
Application Deadline: May 15, 2025, 5pm ET
Learn more about the program, get information session details and access the full request for proposals here: https://centerforbiotechnology.org/what-we-do/technology-development/reach/
[post_title] => Funding Opportunity: Research Evaluation and Commercialization Hub (REACH)Awards
[post_excerpt] => The Center for Biotechnology is pleased to announce a request for proposals for our REACH award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.)
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => news-reach25
[to_ping] =>
[pinged] =>
[post_modified] => 2026-03-10 14:17:16
[post_modified_gmt] => 2026-03-10 18:17:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4804
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 3450
[post_author] => 3
[post_date] => 2020-03-05 14:18:23
[post_date_gmt] => 2020-03-05 14:18:23
[post_content] => The Center for Biotechnology at Stony Brook University has announced the appointment of Dr. Mario R. Mendoza as Executive-In-Residence, and Dr. William Mann as its newest BioEntrepreneur-In-Residence (BEIR). Drs. Mendoza and Mann have extensive bioscience industry experience affording them unique perspectives in their respective roles in residence at the Center for Biotechnology (CFB). Each will work with the CFB and the Long Island Bioscience Hub (LIBH), a collaboration between Stony Brook University, Brookhaven National Laboratory, Cold Spring Harbor Laboratory, and the Feinstein Institute at Northwell Health. Dr. Mann will identify commercially promising academic technologies that have the potential to support company formation while Dr. Mendoza will serve in an advisory capacity for bioscience startup companies in the hub.
Dr. Mario R Mendoza is a clinical anesthesiologist (practiced at the NIH) and currently a healthcare and pharmaceutical industry medical/medical affairs consultant with over 13 years of combined experience in patient clinical care, clinical development, R&D, medical affairs (Abbott, Pfizer and Centrexion Therapeutics), and FDA medical devices regulation. Dr. Mendoza earned his BS degree in chemistry from SUNY College at Old Westbury, and a MS in organic chemistry from the University of Illinois at Urbana-Champaign. He earned his M.D. from the University of Illinois at Chicago College of Medicine and then completed an FDA Commissioner’s Fellowship Program and stayed on at FDA as a Medical Officer/Medical Consultant.
Dr. William R. Mann is Principal of Lodestar Biopharma Solutions LLC, which assists clients in the development of R&D strategies for regulatory and commercial success, business development, and M&A. Previously, he was President and CEO at Helsinn Therapeutics (US), where he transformed the sixteen employee R&D start-up into a profitable commercial company with a team of over one hundred. At Sapphire Therapeutics, Dr. Mann facilitated an investor exit through M&A while managing the company’s lead clinical development program. He also held leadership positions at Novartis in R&D and business development. Dr. Mann holds a PhD in biochemistry from the University of Aberdeen, Scotland and an MBA from Rutgers University.
“We are excited to have Mario and Bill join us at the Center for Biotechnology. Their extensive and varied industry experiences are wonderful assets to our program. The further expansion of our BEIR Program allows us to continue to advance our agenda, fueling the developing bioscience industry in the region” Diane Fabel, Director of Operations at the Center for Biotechnology said.
“I’m thrilled to become an Executive-in-Residence for the Center for Biotechnology.” stated Dr. Mendoza “I’m greatly looking forward to getting involved with biotech industry innovators collaborating with the organization. I believe the bioscience community in the region is robust and the support and partnership with organizations like the Center for Biotechnology are critical in driving innovation in the biotech space, and in getting innovative patient-centric products to market for the benefit of the patient and healthcare provider communities.”
“The work of the Center for Biotechnology is incredibly important to the bioscience community in the region, and I’m eager to be joining the organization.” Dr. Mann stated. “The innovation potential within the region is immense, and I look forward to the collaborative opportunities that lie ahead.”
Dr. Mann will work to identify a technology or technologies from within LIBH partner institutions that will create the foundation for licensing and company formation. He will have the support of the Center for Biotechnology business and technology development staff, as well as the support of external industry advisors to develop successful commercialization strategies. Ultimately, the goal is to help the company position itself for SBIR/STTR grant opportunities, as well as Angel and VC investment. In his role as Executive-in-Residence, Dr. Mendoza will offer invaluable support to the CFB client company portfolio by providing guidance and expertise in diverse areas including, but not limited to, product development, intellectual property strategy, regulatory affairs, capital formation, medical affairs and reimbursement.
The addition of Drs. Mendoza and Mann marks ten entrepreneurs and two executives-in-residence working with the Center for Biotechnology under their BIER program. Collectively, the Center for Biotechnology BEIRS have launched twelve new companies since the program’s inception in 2013.
View PDF announcement.
[post_title] => CFB Announces New Bioentrepreneur & Executive-In-Residence
[post_excerpt] => Joining the Center for Biotechnology as Dr. Mario R. Mendoza as Executive-In-Residence, and Dr. William Mann as BioEntrepreneur-In-Residence (BEIR).
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => cfb-beir-2020
[to_ping] =>
[pinged] =>
[post_modified] => 2020-03-05 15:18:08
[post_modified_gmt] => 2020-03-05 15:18:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3450
[menu_order] => 74
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 5065
[post_author] => 4
[post_date] => 2026-09-01 14:03:32
[post_date_gmt] => 2026-09-01 18:03:32
[post_content] =>
Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.
BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.
Application deadline: October 29, 2026, 5:00pm ET
For info sessions, eligibility and deadlines visit our REACH Website and FAQ.
The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.
Questions? Reach out to our program contacts or sign up for office hours:
Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here
Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here
[post_title] => BioREACH: Translational Research Funding Opportunity
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => bioreach-translational-research-funding-opportunity
[to_ping] =>
[pinged] =>
[post_modified] => 2026-09-04 11:55:36
[post_modified_gmt] => 2026-09-04 15:55:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=5065
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 288
[max_num_pages] => 96
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
[query_cache_key:WP_Query:private] =>
)
